Biotech stocks have been outstanding growth vehicles over the past six-plus years. The industry is still in "hypergrowth" mode because of a number of favorable tailwinds, such as an aging global population that's driving a surge in demand for healthcare products, and the further maturation of game-changing medical technologies such as genome-editing and high-throughput gene sequencing.
As a result, I think investors should have at least one biotech stock in their portfolio heading into 2018. Which biotech stocks offer the best risk-to-reward ratio right now? My recommendations, in order of decreasing market cap, are Celgene Corporation (NASDAQ: CELG), Juno Therapeutics (NASDAQ: JUNO), and Cara Therapeutics (NASDAQ: CARA). Here's why.
Image source: Getty Images.
Source: Fool.com